The Lung Cancer Immune Prognostic Score predicts pathologic complete response and survival in NSCLC patients receiving neoadjuvant immunochemotherapy
IntroductionNeoadjuvant immunochemotherapy (nICT) has significantly improved event-free survival (EFS) and pathologic complete response (pCR) in patients with resectable non-small cell lung cancer (NSCLC). However, the lack of validated biomarkers limits their ability to predict therapeutic efficacy...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1567565/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850201956891492352 |
|---|---|
| author | Yuyan Xie Zhihao Shi Tong Chen Hongyan Li Menglin Fan Xuqin Xiang Fang Liu |
| author_facet | Yuyan Xie Zhihao Shi Tong Chen Hongyan Li Menglin Fan Xuqin Xiang Fang Liu |
| author_sort | Yuyan Xie |
| collection | DOAJ |
| description | IntroductionNeoadjuvant immunochemotherapy (nICT) has significantly improved event-free survival (EFS) and pathologic complete response (pCR) in patients with resectable non-small cell lung cancer (NSCLC). However, the lack of validated biomarkers limits their ability to predict therapeutic efficacy and survival outcomes. This study aimed to develop a novel inflammatory and nutritional index, the Lung Cancer Immune Prognostic Score (LCIPS), to predict pCR and survival prognosis in patients with NSCLC.MethodsThis retrospective study included 131 patients with clinical stage IB-IIIB NSCLC who underwent neoadjuvant immunochemotherapy between May 2020 and May 2024. Baseline clinical data and hematological parameters were collected. Lasso regression analysis was employed to identify hematological indices associated with pCR, and the LCIPS was constructed based on these factors. Kaplan-Meier survival analysis and log-rank tests were used to assess survival differences. Logistic regression was performed to identify the predictors of pCR, while Cox regression analysis determined independent prognostic factors for disease-free survival (DFS) and overall survival (OS). The predictive performance of the LCIPS was validated using a nomogram.ResultsLasso regression identified three core hematological indices: the albumin-to-globulin ratio (A/G), absolute monocyte count (MONO), and absolute lymphocyte count (LYM). The LCIPS formula was as follows: LCIPS=0.900×A/G+0.761×MONO (109/L) −0.065×LYM (109/L). Receiver operating characteristic (ROC) curve analysis showed that the LCIPS had superior predictive efficacy (area under the curve (AUC) = 0.68) compared to other classical markers. Univariate and multivariate logistic regression analyses identified intraoperative lymph node dissection status and A/G and LCIPS as independent predictors of pCR (p < 0.05). Multivariate Cox regression analysis demonstrated that smoking status and LCIPS were independent prognostic factors for DFS and OS. Nomogram validation indicated robust predictive accuracy for LCIPS. Notably, among immune-related adverse events (irAEs), endocrine- and cardiac-related irAEs significantly affected DFS (p < 0.05).DiscussionLCIPS is an independent predictor of pCR in patients with NSCLC receiving neoadjuvant immunochemotherapy and is associated with improved DFS and survival outcomes. This novel index offers valuable guidance for personalized treatment strategies. |
| format | Article |
| id | doaj-art-152af31b1a2e4da9849a746d06ef8592 |
| institution | OA Journals |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-152af31b1a2e4da9849a746d06ef85922025-08-20T02:11:53ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-04-011610.3389/fimmu.2025.15675651567565The Lung Cancer Immune Prognostic Score predicts pathologic complete response and survival in NSCLC patients receiving neoadjuvant immunochemotherapyYuyan XieZhihao ShiTong ChenHongyan LiMenglin FanXuqin XiangFang LiuIntroductionNeoadjuvant immunochemotherapy (nICT) has significantly improved event-free survival (EFS) and pathologic complete response (pCR) in patients with resectable non-small cell lung cancer (NSCLC). However, the lack of validated biomarkers limits their ability to predict therapeutic efficacy and survival outcomes. This study aimed to develop a novel inflammatory and nutritional index, the Lung Cancer Immune Prognostic Score (LCIPS), to predict pCR and survival prognosis in patients with NSCLC.MethodsThis retrospective study included 131 patients with clinical stage IB-IIIB NSCLC who underwent neoadjuvant immunochemotherapy between May 2020 and May 2024. Baseline clinical data and hematological parameters were collected. Lasso regression analysis was employed to identify hematological indices associated with pCR, and the LCIPS was constructed based on these factors. Kaplan-Meier survival analysis and log-rank tests were used to assess survival differences. Logistic regression was performed to identify the predictors of pCR, while Cox regression analysis determined independent prognostic factors for disease-free survival (DFS) and overall survival (OS). The predictive performance of the LCIPS was validated using a nomogram.ResultsLasso regression identified three core hematological indices: the albumin-to-globulin ratio (A/G), absolute monocyte count (MONO), and absolute lymphocyte count (LYM). The LCIPS formula was as follows: LCIPS=0.900×A/G+0.761×MONO (109/L) −0.065×LYM (109/L). Receiver operating characteristic (ROC) curve analysis showed that the LCIPS had superior predictive efficacy (area under the curve (AUC) = 0.68) compared to other classical markers. Univariate and multivariate logistic regression analyses identified intraoperative lymph node dissection status and A/G and LCIPS as independent predictors of pCR (p < 0.05). Multivariate Cox regression analysis demonstrated that smoking status and LCIPS were independent prognostic factors for DFS and OS. Nomogram validation indicated robust predictive accuracy for LCIPS. Notably, among immune-related adverse events (irAEs), endocrine- and cardiac-related irAEs significantly affected DFS (p < 0.05).DiscussionLCIPS is an independent predictor of pCR in patients with NSCLC receiving neoadjuvant immunochemotherapy and is associated with improved DFS and survival outcomes. This novel index offers valuable guidance for personalized treatment strategies.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1567565/fullneoadjuvant immunochemotherapynon-small cell lung cancerpathologic complete responseinflammatory and nutritional indicesprognostic factors |
| spellingShingle | Yuyan Xie Zhihao Shi Tong Chen Hongyan Li Menglin Fan Xuqin Xiang Fang Liu The Lung Cancer Immune Prognostic Score predicts pathologic complete response and survival in NSCLC patients receiving neoadjuvant immunochemotherapy Frontiers in Immunology neoadjuvant immunochemotherapy non-small cell lung cancer pathologic complete response inflammatory and nutritional indices prognostic factors |
| title | The Lung Cancer Immune Prognostic Score predicts pathologic complete response and survival in NSCLC patients receiving neoadjuvant immunochemotherapy |
| title_full | The Lung Cancer Immune Prognostic Score predicts pathologic complete response and survival in NSCLC patients receiving neoadjuvant immunochemotherapy |
| title_fullStr | The Lung Cancer Immune Prognostic Score predicts pathologic complete response and survival in NSCLC patients receiving neoadjuvant immunochemotherapy |
| title_full_unstemmed | The Lung Cancer Immune Prognostic Score predicts pathologic complete response and survival in NSCLC patients receiving neoadjuvant immunochemotherapy |
| title_short | The Lung Cancer Immune Prognostic Score predicts pathologic complete response and survival in NSCLC patients receiving neoadjuvant immunochemotherapy |
| title_sort | lung cancer immune prognostic score predicts pathologic complete response and survival in nsclc patients receiving neoadjuvant immunochemotherapy |
| topic | neoadjuvant immunochemotherapy non-small cell lung cancer pathologic complete response inflammatory and nutritional indices prognostic factors |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1567565/full |
| work_keys_str_mv | AT yuyanxie thelungcancerimmuneprognosticscorepredictspathologiccompleteresponseandsurvivalinnsclcpatientsreceivingneoadjuvantimmunochemotherapy AT zhihaoshi thelungcancerimmuneprognosticscorepredictspathologiccompleteresponseandsurvivalinnsclcpatientsreceivingneoadjuvantimmunochemotherapy AT tongchen thelungcancerimmuneprognosticscorepredictspathologiccompleteresponseandsurvivalinnsclcpatientsreceivingneoadjuvantimmunochemotherapy AT hongyanli thelungcancerimmuneprognosticscorepredictspathologiccompleteresponseandsurvivalinnsclcpatientsreceivingneoadjuvantimmunochemotherapy AT menglinfan thelungcancerimmuneprognosticscorepredictspathologiccompleteresponseandsurvivalinnsclcpatientsreceivingneoadjuvantimmunochemotherapy AT xuqinxiang thelungcancerimmuneprognosticscorepredictspathologiccompleteresponseandsurvivalinnsclcpatientsreceivingneoadjuvantimmunochemotherapy AT fangliu thelungcancerimmuneprognosticscorepredictspathologiccompleteresponseandsurvivalinnsclcpatientsreceivingneoadjuvantimmunochemotherapy AT yuyanxie lungcancerimmuneprognosticscorepredictspathologiccompleteresponseandsurvivalinnsclcpatientsreceivingneoadjuvantimmunochemotherapy AT zhihaoshi lungcancerimmuneprognosticscorepredictspathologiccompleteresponseandsurvivalinnsclcpatientsreceivingneoadjuvantimmunochemotherapy AT tongchen lungcancerimmuneprognosticscorepredictspathologiccompleteresponseandsurvivalinnsclcpatientsreceivingneoadjuvantimmunochemotherapy AT hongyanli lungcancerimmuneprognosticscorepredictspathologiccompleteresponseandsurvivalinnsclcpatientsreceivingneoadjuvantimmunochemotherapy AT menglinfan lungcancerimmuneprognosticscorepredictspathologiccompleteresponseandsurvivalinnsclcpatientsreceivingneoadjuvantimmunochemotherapy AT xuqinxiang lungcancerimmuneprognosticscorepredictspathologiccompleteresponseandsurvivalinnsclcpatientsreceivingneoadjuvantimmunochemotherapy AT fangliu lungcancerimmuneprognosticscorepredictspathologiccompleteresponseandsurvivalinnsclcpatientsreceivingneoadjuvantimmunochemotherapy |